- LIBRETTO-321, a phase II study of the efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancer (TC)Zheng, X.; Ji, Q.; Sun, Y.; Ge, M.; Zhang, B.; Cheng, Y.; Lei, S.; Shi, F.; Zhang, W.; Gao, M.ESMO Targeted Anticancer Therapies Congress (TAT), ELECTR NETWORK, 2022-03-07 To 2022-03-08.被引 1
- Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterationsYang, J-J.; Zhang, Y.; Wu, L.; Hu, J.; Wang, Z-H.; Chen, J-H.; Fan, Y.; Lin, G.; Wang, Q-M.; Yao, Y.; Zhao, J.; Chen, Y.; Fang, J.; Song, Y.; Zhang, W.; Cheng, Y.; Guo, R-H.; Li, X-Y.; Li, A-N.; Wu, Y-L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II studyZhou, Q.; Meng, X.; Sun, L.; Huang, D.; Yang, N.; Yu, Y.; Zhao, M.; Zhuang, W.; Hu, Y.; Pan, Y.; Sun, M.; Shan, J.; Guo, R-H.; Chu, Q.; Xu, C.; Lin, J.; Huang, J.; Huang, M.; Shen, Y.; Wu, Y-L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors
9阅读
